Transfusion-Dependent Beta Thalassemia (TDT)

Beta thalassemia is an inherited disorder of hemoglobin synthesis leading to ineffective erythropoiesis and severe anemia. TDT patients require lifelong transfusions and iron chelation to prevent organ damage.

Symptoms & Presentation

• Severe anemia in infancy (pallor, failure to thrive)
• Bone marrow expansion causing facial bone deformities, osteoporosis
• Splenomegaly, hepatomegaly
• Growth delay, delayed puberty
• Iron overload complications (cardiac, hepatic, endocrine)

Diagnosis

• CBC: microcytic, hypochromic anemia
• Hemoglobin electrophoresis: elevated HbF, HbA2; absent/reduced HbA
• Genetic testing for β-globin gene mutations
• Serum ferritin, liver iron concentration (MRI), cardiac T2* MRI for iron loading

Management

Transfusion Therapy

• Regular packed RBC transfusions (every 2–4 weeks) to maintain pretransfusion Hb ≥9–10 g/dL
• Use phenotype-matched, leukoreduced, irradiated units
• Monitor for transfusion reactions and alloimmunization

Iron Chelation

• Deferoxamine (parenteral), deferasirox (oral), deferiprone (oral) used alone or in combination
• Adjust based on ferritin, liver/cardiac iron (MRI)
• Adherence critical to prevent cardiomyopathy/endocrinopathies

Splenectomy

• Considered for hypersplenism increasing transfusion needs; requires vaccination and prophylactic antibiotics

Endocrine & Organ Surveillance

• Annual endocrine assessments (thyroid, glucose, sex hormones)
• Bone density scans, vitamin D/calcium supplementation
• Cardiac MRI T2* every 1–2 years; echocardiogram, liver ultrasound

Curative Options

• Allogeneic hematopoietic stem cell transplant (HSCT) in childhood/young adults with matched donor
• Gene therapy: betibeglogene autotemcel (LentiGlobin) approved in some regions; CRISPR gene editing (exa-cel) under evaluation

Lifestyle & Support

• Track transfusions, chelation doses, labs, imaging, vaccinations
• Nutrition: adequate calories, low iron intake, avoid iron/vitamin C supplements unless prescribed
• Exercise within tolerance; avoid contact sports if splenomegalic
• Psychosocial support for chronic medical visits and body-image concerns

Complications

• Iron overload: cardiomyopathy, arrhythmias, liver cirrhosis, endocrine failure
• Infections (due to transfusions/splenectomy)
• Alloimmunization causing transfusion delays
• Thromboembolic events

Research & Future Directions

Gene editing, fetal hemoglobin induction, improved iron chelators, and novel agents targeting ineffective erythropoiesis (luspatercept) are reshaping care.

Experimental & Emerging Treatments

• Gene Editing (CRISPR/Cas9): Reactivating HbF by disrupting BCL11A enhancers.
• Luspatercept: Erythroid maturation agent reducing transfusion burden in some patients.
• Improved Chelation Delivery: Long-acting depot formulations to boost adherence.
• Digital Twins: Modeling iron kinetics to personalize chelation dosing.

Track Thalassemia with Diagnoza.care

Stay in Range Between Transfusions – Log transfusion dates, Hb levels, ferritin, liver/cardiac iron MRI, chelation regimens, endocrine labs, imaging, vaccinations, and transplant/gene therapy evaluations; capture side effects; and let the AI companion remind you of appointments and dosing schedules.

---

Medical Disclaimer: Informational only. Work with your hematologist/transfusion center for individualized transfusion plans, chelation monitoring, and curative therapy eligibility. Sources: Thalassemia International Federation, American Society of Hematology, Cooley's Anemia Foundation